Jing Zhou, Ming Jing, Ming Liu, Liya Fang, Luan Yang, Guizhi Qiao
{"title":"阿普米司特治疗急性地衣样变糠疹1例。","authors":"Jing Zhou, Ming Jing, Ming Liu, Liya Fang, Luan Yang, Guizhi Qiao","doi":"10.1080/09546634.2025.2562302","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the efficacy and safety of apremilast, a phosphodiesterase-4 (PDE-4) inhibitor, in treating pityriasis lichenoides et varioliformis acuta (PLEVA) and explore its potential mechanisms.</p><p><strong>Methods: </strong>We present a 16-year-old male with refractory PLEVA who failed conventional therapies (systemic corticosteroids, acitretin). Treatment with oral apremilast (30 mg twice daily) was initiated.</p><p><strong>Results: </strong>Significant improvement was observed within 1 week, with near-complete clearance by 8 weeks. No relapse or adverse events occurred during 12-month follow-up.</p><p><strong>Conclusions: </strong>Apremilast may be a safe and effective option for refractory PLEVA.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2562302"},"PeriodicalIF":3.9000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Apremilast in the treatment of pityriasis lichenoides et varioliformis acuta: a case report.\",\"authors\":\"Jing Zhou, Ming Jing, Ming Liu, Liya Fang, Luan Yang, Guizhi Qiao\",\"doi\":\"10.1080/09546634.2025.2562302\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To evaluate the efficacy and safety of apremilast, a phosphodiesterase-4 (PDE-4) inhibitor, in treating pityriasis lichenoides et varioliformis acuta (PLEVA) and explore its potential mechanisms.</p><p><strong>Methods: </strong>We present a 16-year-old male with refractory PLEVA who failed conventional therapies (systemic corticosteroids, acitretin). Treatment with oral apremilast (30 mg twice daily) was initiated.</p><p><strong>Results: </strong>Significant improvement was observed within 1 week, with near-complete clearance by 8 weeks. No relapse or adverse events occurred during 12-month follow-up.</p><p><strong>Conclusions: </strong>Apremilast may be a safe and effective option for refractory PLEVA.</p>\",\"PeriodicalId\":94235,\"journal\":{\"name\":\"The Journal of dermatological treatment\",\"volume\":\"36 1\",\"pages\":\"2562302\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of dermatological treatment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/09546634.2025.2562302\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatological treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/09546634.2025.2562302","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/18 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Apremilast in the treatment of pityriasis lichenoides et varioliformis acuta: a case report.
Objectives: To evaluate the efficacy and safety of apremilast, a phosphodiesterase-4 (PDE-4) inhibitor, in treating pityriasis lichenoides et varioliformis acuta (PLEVA) and explore its potential mechanisms.
Methods: We present a 16-year-old male with refractory PLEVA who failed conventional therapies (systemic corticosteroids, acitretin). Treatment with oral apremilast (30 mg twice daily) was initiated.
Results: Significant improvement was observed within 1 week, with near-complete clearance by 8 weeks. No relapse or adverse events occurred during 12-month follow-up.
Conclusions: Apremilast may be a safe and effective option for refractory PLEVA.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
